vimarsana.com

Page 26 - முதலீட்டாளர் உறவுகள் தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lincoln Electric Holdings Inc (LECO) Q4 2020 Earnings Call Transcript

Operator Greetings and welcome to Lincoln Electric 2020 Fourth Quarter Financial Results Conference Call. [Operator Instructions] And this call is being recorded. It is my pleasure to introduce your host, Amanda Butler, Vice President of Investor Relations and Communications. Thank you. You may begin. Amanda Butler Vice President, Investor Relations & Communications Thank you, Michelle, and good morning, everyone. Welcome to Lincoln Electric s 2020 fourth quarter conference call. We released our financial results earlier today and you can find our release as an attachment to this call s slide presentation as well as on the Lincoln Electric website at lincolnelectric.com in the Investor Relations section. Joining me on the call today is Chris Mapes, Lincoln s Chairman, President and Chief Executive Officer; and Gabe Bruno, our Chief Financial Officer. Chris will begin the discussion with an overview of our annual sales results and business trends and Gabe will cover our fourth

Prothena Corporation plc: Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

Prothena Corporation plc: Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update VITAL study 9-month results expected to be presented at medical conference in 2021 Prasinezumab New pre-specified exploratory subgroup analyses from Part 1 of the Phase 2 PASADENA study to be presented at the 15th International Conference for Alzheimer s and Parkinson s Diseases in March 2021 (ADPD 2021) $60 million clinical milestone payment to be achieved upon first patient dosed in late-stage Phase 2b study in patients with early Parkinson s disease; further details expected in 2Q 2021 Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference

Lucara 2020 Year End Results To Be Released Monday, February 22, 2021

Prothena Corporation plc: Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena Corporation plc: Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in connection with hiring three new employees, the compensation committee of the Company s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 75,000 ordinary shares of the Company. The options have an exercise price per share equal to $11.00, which was the closing trading price on February 1, 2021, the date of the grants. The inducement awards will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grants and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The options

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.